Status:
TERMINATED
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Lead Sponsor:
Biogen
Conditions:
Progressive Multifocal Leukoencephalopathy
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML). Samp...
Detailed Description
Deoxyribonucleic acid (DNA) will be analyzed from natalizumab-treated subjects who develop Progressive Multifocal Leukoencephalopathy (PML). The genetic analysis of the subjects will directly seek mut...
Eligibility Criteria
Inclusion
- Key Inclusion Criteria:
- Subjects who have confirmed PML while on treatment with Natalizumab
- NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01211639
Start Date
October 1 2010
End Date
August 1 2014
Last Update
January 19 2015
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
North Central Neurology Associates
Cullman, Alabama, United States, 35058
2
Rocky Mountain MS Center at Anschutz Medical Campus University Colorado Denver
Aurora, Colorado, United States, 80045
3
Rush Medical Center - Rush Multiple Sclerosis Center
Chicago, Illinois, United States, 60612
4
St. Vincent Hospital, St. Vincent Neuroscience Institute
Indianapolis, Indiana, United States, 46260